Brief: Jama Oncology Highlights Plinabulin's Efficacy In Preventing Chemotherapy-Induced Neutropenia As A Monotherapy
29/09/2020 13:48
Sept 29 (Reuters) - Beyondspring Inc BYSI.O :
* JAMA ONCOLOGY HIGHLIGHTS PLINABULIN'S EFFICACY IN
PREVENTING
CHEMOTHERAPY-INDUCED NEUTROPENIA AS A MONOTHERAPY
Source text for Eikon: ID:nGNX1Q6M2Q
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value